⚠ Evidence warning: Clinical trials or other evidence do not support the claim that Turkey Tail, or the shiitake extract AHCC (active hexose correlated compound), clears persistent human papillomavirus (HPV) infection and reverses low-grade cervical lesions. This page keeps it as a report of what people, websites or other media say.
Turkey Tail for Human Papillomavirus (HPV) and Cervical Dysplasia
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide; over 80% of sexually active adults will be exposed during their lifetime. The majority of infections clear spontaneously within 12-24 months via natural killer (NK) cell and cytotoxic T-cell-mediated immune surveillance. A minority (approximately 10%) persist as chronic infection and become the precursor to cervical, anal, oropharyngeal, vulvar, vaginal, and penile cancers. The clinical interest in medicinal mushroom polysaccharides for human papillomavirus management stems from small pilot studies of AHCC (active hexose correlated compound, a related shiitake-derived polysaccharide-rich extract sharing immune-modulating pharmacology with Turkey Tail), in which 4 of 6 women with persistent high-risk human papillomavirus had confirmed clearance after 3-6 months of AHCC 3 g a day (Smith 2019), and from a 2022 randomized placebo-controlled trial of AHCC by the same group. The proposed mechanism is enhancement of endogenous natural killer cell-mediated and dendritic cell-coordinated viral clearance from infected cervical keratinocytes. Direct Turkey Tail human papillomavirus studies are more limited: a preliminary 2-month oral study in people with gingivitis (Donatini 2014) and trials of a Coriolus versicolor-based vaginal gel.
Table of Contents
- Human Papillomavirus Biology and Natural History
- Why Some Infections Persist and Most Clear
- The First AHCC Pilot Studies (Smith 2019)
- The 2022 Phase II Randomized Trial of AHCC
- Direct Coriolus versicolor (Turkey Tail) Studies
- Turkey Tail as a Vaginal Gel: The PALOMA Trial
- Mechanism: Natural Killer Cell-Mediated Keratinocyte Clearance
- Cervical Dysplasia Staging & Management
- Doses Used in the Trials and What They Found
- Integration with Conventional Care
- Other Human Papillomavirus-Associated Sites (Oropharyngeal, Anal)
- Cautions and Limitations of the Evidence
- Key Research Papers
- Connections
- Featured Videos
Human Papillomavirus Biology and Natural History
Human papillomaviruses are small, non-enveloped, double-stranded DNA viruses that infect basal keratinocytes of stratified squamous epithelium. Over 200 human papillomavirus types have been characterized, of which approximately 40 infect the anogenital tract and 14 are designated "high-risk" because of their oncogenic potential. The two most important high-risk types are HPV-16 (cause of approximately 50% of cervical cancers worldwide) and HPV-18 (cause of approximately 15-20% of cervical cancers). Other high-risk types include HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
The natural history of human papillomavirus infection involves several stages:
- Initial infection — human papillomavirus enters basal keratinocytes through microabrasions in the epithelium during sexual contact
- Productive infection — virus replicates in the differentiating epithelium, producing infectious virions in the superficial layers that shed into bodily secretions
- Spontaneous clearance — in 80-90% of cases, the immune system clears the infection within 12-24 months
- Persistent infection — in approximately 10% of cases, the virus persists and can be detected on repeat testing more than 24 months later. Persistence is the strongest risk factor for progression to dysplasia and cancer.
- Cervical intraepithelial neoplasia (CIN) — persistent high-risk human papillomavirus infection can drive progression through CIN 1 (mild dysplasia), CIN 2 (moderate), and CIN 3 (severe)
- Invasive cancer — CIN 3 lesions can progress to invasive cervical cancer over 5-15 years if untreated; this transition is the rate-limiting step that screening (Pap smear, human papillomavirus testing) is designed to interrupt
The clinical opportunity for immune-modulating intervention is concentrated in stages 3-5: at the persistent-infection / low-grade-dysplasia transition, where the immune system has demonstrably failed to clear the virus on its own and there is still an opportunity to restore that clearance before higher-grade lesions develop. This is the window targeted by the AHCC and Turkey Tail trials.
Why Some Infections Persist and Most Clear
The 80-90% spontaneous clearance rate vs the 10% persistence rate is one of the most important questions in human papillomavirus biology. The factors identified as contributing to persistence include:
- Human papillomavirus type — HPV-16 has the lowest spontaneous clearance rate of any high-risk type
- Viral load — higher initial viral load correlates with higher persistence rate
- Immune competence — human immunodeficiency virus (HIV) infection, organ transplant immunosuppression, chemotherapy, and aging all increase persistence rate
- Smoking — smokers have approximately 2x the persistence rate of non-smokers, due to direct immunosuppressive effects of tobacco smoke on cervical natural killer cells and Langerhans cells
- Co-infection — herpes simplex virus type 2 (HSV-2), Chlamydia trachomatis, and bacterial vaginosis all increase human papillomavirus persistence
- Nutritional status — folate, Vitamin B12, Vitamin A, Vitamin C, and Vitamin E deficiencies are individually associated with increased persistence
- Human leukocyte antigen (HLA) type — certain human leukocyte antigen class I and II alleles are associated with more vs less effective human papillomavirus clearance
- Natural killer cell function — reduced natural killer cell function is consistently associated with human papillomavirus persistence and progression
- Local immune microenvironment — the cervical immune microenvironment, including Langerhans cells, intraepithelial lymphocytes, and the cervical microbiome, all influence clearance
The therapeutic premise of immune-modulating therapy is that some persistent infections result from suboptimal natural killer cell and dendritic cell function, and that restoring this function can permit clearance even after years of viral persistence. The clinical trial data supports this premise, at least for a meaningful subset of patients.
The First AHCC Pilot Studies (Smith 2019)
The first published human data on AHCC for human papillomavirus come from a 2019 paper in Frontiers in Oncology by Judith Smith and colleagues, which took the extract “from bench to bedside”: cervical cancer cells in the dish, a mouse study, and two small pilot studies in women.
- Cell and mouse work: cervical cancer cell lines were treated with AHCC 0.42 mg/mL daily for 7 days, and mice carrying cervical cancer tumors were dosed with AHCC 50 mg/kg/d for 90 days; the authors report that human papillomavirus clearance was observed in the cells and confirmed in the animal studies as a durable response
- Two pilot studies of 10 patients each, in women with confirmed persistent high-risk human papillomavirus infections
- The first pilot tested AHCC 3 g from 5 weeks up to 6 months; the second tested AHCC 1 g for under 8 months
- High-risk human papillomavirus DNA status and an immune panel were checked at each visit
Results:
- 4 of 6 (66.7%) patients had confirmed high-risk human papillomavirus clearance after 3-6 months of AHCC 3 g
- 4 of 9 (44%) patients had confirmed clearance after 7 months of AHCC 1 g
- Suppression of interferon-beta (IFNβ) below 25 pg/mL was observed in those clearing the infection
The pilots were small and had no placebo group, so their results are preliminary — the authors’ own word. They noted that a confirmatory phase II randomized, double-blinded, placebo-controlled study was ongoing; that trial is described in the next section.
Note: AHCC (active hexose correlated compound) is not Turkey Tail. The 2022 trial describes it as a proprietary, standardized extract of cultured shiitake (Lentinula edodes) mycelia. Its bioactive constituents are alpha-glucans and beta-glucans, with mechanism of action that overlaps with but is not identical to Turkey Tail polysaccharide-K (PSK) / polysaccharopeptide (PSP). Because AHCC is the extract with the formal human papillomavirus clinical trial data, this discussion focuses on AHCC results while noting the mechanistic convergence with Turkey Tail. Direct Turkey Tail human papillomavirus studies are more limited (Donatini 2014, a preliminary 2-month oral study, and the vaginal-gel studies described below).
The 2022 Phase II Randomized Trial of AHCC
Judith Smith has been the principal investigator on the more formal follow-up trials of AHCC for human papillomavirus. The Smith 2022 study in Frontiers in Oncology reported a phase II randomized, double-blind, placebo-controlled trial in 50 women with persistent high-risk human papillomavirus infection.
Smith 2022 design:
- 50 women over 30 years of age with confirmed persistent high-risk human papillomavirus infections for greater than 2 years
- Randomized to AHCC 3 g by mouth once daily on an empty stomach for 6 months followed by 6 months of placebo (25 women), or to placebo once daily for 12 months (25 women)
- Every 3 months: human papillomavirus DNA and RNA testing, and a blood panel of immune markers (interferon-alpha, interferon-beta, interferon-gamma, IgG1, T lymphocytes and natural killer cell levels)
- After the 12 months, women on the placebo arm could choose to take AHCC unblinded for 6 months
Results:
- 50 women were enrolled, and 41 completed the study
- 14 of 22 (63.6%) women in the AHCC arm were human papillomavirus RNA/DNA negative after 6 months; 64.3% (9/14) of them stayed negative 6 months off the supplement
- 2 of 19 (10.5%) women on the placebo arm were human papillomavirus negative at 12 months
- Of the 12 placebo-arm women who went on to take AHCC unblinded, 50% (6) were negative after 6 months; across all 34 women who received AHCC, the overall response rate was 58.8%
- Suppression of interferon-beta (IFN-β) to less than 20 pg/ml correlated with an increase in T lymphocytes and interferon-gamma (IFN-γ) and with durable clearance in women who received AHCC (the mean interferon-beta level at enrolment was 60.5 ± 37.6 pg/ml)
- AHCC was well tolerated, with no significant adverse side effects reported
The Smith 2022 trial is the most rigorous evidence to date for a medicinal mushroom polysaccharide intervention in human papillomavirus. Within the trial, 63.6% of AHCC-treated women were negative at 6 months, against 10.5% of placebo-treated women at 12 months. The immune correlate the authors report — suppression of interferon-beta together with a rise in T lymphocytes and interferon-gamma — is consistent with the immune-mediated viral clearance hypothesis.
A larger Phase III randomized trial is needed to confirm these findings and to define the optimal duration of treatment, the optimal patient population, and the durability of clearance after stopping treatment; the authors write that “The duration of AHCC supplementation required beyond the first negative result needs more evaluation.”
Direct Coriolus versicolor (Turkey Tail) Studies
The direct Turkey Tail (Coriolus versicolor) human papillomavirus evidence base is smaller than the AHCC evidence:
- Donatini 2014 (International Journal of Medicinal Mushrooms) — a preliminary randomized study of oral human papillomavirus (types 16 and 18). Of 472 patients who had mouth swabs for gingivitis, 61 were positive for HPV-16 or HPV-18; 41 took Coriolus versicolor (Trametes versicolor) plus Ganoderma lucidum (Reishi) and 20 took another mushroom, Laetiporus sulphureus, for 2 months. Clearance on polymerase chain reaction testing after 2 months was 88% in the Coriolus + Ganoderma group and 5% in the comparison group (P<0.001). The study measured virus on mouth swabs, not lesions.
- Portuguese clinical observations — Portuguese clinicians have reported favorable observations in women with human papillomavirus-positive cervical lesions treated with Coriolus versicolor extract. These are practitioner reports; no indexed publication of them was found.
Most of the European Turkey Tail data now concern a Coriolus versicolor-based vaginal gel rather than an oral supplement. A 2026 scoping review of the gel found five eligible studies: one randomized trial of 91 women, one sub-analysis of that trial (41 women), and three cohort studies of 183, 192 and 21 women. It reported regression rates of 76.1–84.9% in treated women compared with 40.8–64.5% in untreated controls, and no serious adverse events, and it describes the gel’s efficacy and safety as “promising but preliminary.”
The oral studies are small and short, so the evidence is weaker than the randomized AHCC data, though the direction of effect is consistent with it.
Turkey Tail as a Vaginal Gel: The PALOMA Trial
The randomized trial of a Turkey Tail product for cervical human papillomavirus used a Coriolus versicolor-based vaginal gel, not a capsule. The PALOMA study (2021) was a multicenter, open-label, randomized trial in 91 HPV-positive women with low-grade Pap smear changes and matching colposcopy, comparing the gel with a watchful-waiting (no treatment) approach.
- Normal Pap smear with matching colposcopy at 3 and 6 months: 78.0% and 84.9% with the gel, against 54.8% and 64.5% without treatment
- Overall human papillomavirus clearance at 6 months: 59.6% with the gel against 41.9% without; in high-risk types, 62.5% against 40.0%
- 7 possible or probable treatment-related adverse events were reported, most of them (6) mild or moderate
The trial was open-label (everyone knew who received the gel), and the 2026 FIGO/IGCS statement described in the integration section raises further concerns about the gel studies.
Mechanism: Natural Killer Cell-Mediated Keratinocyte Clearance
The mechanism by which medicinal mushroom polysaccharides facilitate human papillomavirus clearance is the same natural killer cell potentiation mechanism discussed at length in our immune surveillance deep-dive, with specific application to human papillomavirus-infected cervical keratinocytes.
The key steps:
- Human papillomavirus-infected keratinocytes downregulate major histocompatibility complex (MHC) class I — human papillomavirus E5, E6, and E7 proteins reduce surface MHC class I expression as an immune-evasion strategy. This protects against cytotoxic T-cell recognition but creates a "missing self" signature that natural killer cells specifically target.
- Natural killer cells in the cervical mucosa recognize human papillomavirus-infected cells — intraepithelial natural killer cells expressing activating receptors (NKG2D, NKp30, NKp44, NKp46) recognize stress ligands on infected keratinocytes
- Natural killer cells deliver cytotoxic granules — perforin and granzyme B induce apoptosis in the target cell, eliminating the infected keratinocyte before it can produce more virions
- Dendritic cells acquire viral antigens from apoptotic cells — cross-presentation of human papillomavirus antigens on dendritic cell MHC class I drives expansion of human papillomavirus-specific cytotoxic T cells
- Human papillomavirus-specific T cells provide durable surveillance — memory CD8+ T cells specific for human papillomavirus E6 and E7 oncoproteins provide long-term protection against recurrence
Turkey Tail and AHCC act at step 2-3 by potentiating natural killer cell activity and at step 4 by enhancing dendritic cell antigen presentation. The net effect is acceleration of the same physiologic clearance mechanism that successfully clears human papillomavirus in the 80-90% of immunocompetent individuals who never develop persistent infection.
This is important conceptually: the mushroom extracts are not directly antiviral in the sense of acyclovir for herpes. They do not inhibit human papillomavirus replication, do not target viral proteins, and have no direct effect on infected cells. They restore the host immune-mediated clearance mechanism, which then does the actual work of eliminating the infection.
Cervical Dysplasia Staging & Management
The staging system and the standard-of-care management for human papillomavirus-related cervical changes:
- Human papillomavirus positive, normal cytology — most common scenario after introduction of human papillomavirus cotesting. Standard management is repeat human papillomavirus testing in 12 months.
- ASCUS (atypical squamous cells of undetermined significance) — intermediate finding. Standard management depends on age and human papillomavirus status; often repeat in 6-12 months.
- LSIL (low-grade squamous intraepithelial lesion, equivalent to CIN 1) — mild dysplasia. Most spontaneously regress. Standard management is colposcopy and repeat testing in 6 months.
- HSIL (high-grade squamous intraepithelial lesion, equivalent to CIN 2 or CIN 3) — significant dysplasia with substantial cancer progression risk. Standard management is LEEP (loop electrosurgical excision procedure) or cold knife conization. Turkey Tail is NOT a substitute for excisional treatment of HSIL.
- Invasive cervical cancer — requires conventional oncology treatment (surgery, radiation, chemotherapy). Turkey Tail’s role as an adjunct is covered on the PSK / PSP page; it is not a primary treatment.
The Smith 2022 AHCC trial enrolled women over 30 years of age with confirmed persistent high-risk human papillomavirus infection for more than 2 years; its abstract does not describe enrolment by cytology category. The PALOMA gel trial enrolled women with low-grade Pap smear changes. For HSIL/CIN 2-3 or invasive cancer, conventional excisional or oncologic treatment is the standard of care.
Doses Used in the Trials and What They Found
The doses and durations the human studies used, and related points from the evidence:
- AHCC — 3 g by mouth once daily on an empty stomach for 6 months, followed by 6 months of placebo, in the 2022 randomized trial (Smith 2022). The 2019 pilots used AHCC 3 g from 5 weeks up to 6 months, and AHCC 1 g for under 8 months.
- Turkey Tail — the oral study (Donatini 2014) gave Coriolus versicolor together with Ganoderma lucidum for 2 months; the PALOMA trial used a Coriolus versicolor-based vaginal gel for 6 months.
- Nutrition — folate, Vitamin B12, Vitamin A or beta-carotene, Vitamin C, Vitamin E, selenium and zinc have each been individually associated with reduced human papillomavirus persistence.
- Modifiable risk factors — smoking and co-existing infections (herpes simplex virus type 2, chlamydia, bacterial vaginosis) are linked to persistence, as listed in the persistence section above.
- Surveillance — the 2026 FIGO/IGCS statement (see the next section) states that evidence-based surveillance remains the standard of care.
- Testing in the trial — the 2022 AHCC trial checked human papillomavirus DNA and RNA every 3 months.
What the trials found:
- In the 2022 randomized trial, 63.6% (14 of 22) of women in the AHCC arm were negative after 6 months, and 64.3% (9 of 14) of them stayed negative 6 months off the supplement; across all 34 women who received AHCC, the overall response rate was 58.8%
- In the PALOMA gel trial, 84.9% of treated women had a normal Pap smear with matching colposcopy at 6 months, compared with 64.5% without treatment
- Some users report improvement in subjective immune-related symptoms (energy, frequency of incidental infections), separate from human papillomavirus results
Integration with Conventional Care
Turkey Tail and AHCC have been studied as additions to, not substitutes for, standard human papillomavirus / cervical dysplasia management. How they relate to conventional care:
- Surveillance is the standard of care — human papillomavirus testing, cytology, colposcopy, and biopsy as indicated
- Interactions — there is no documented negative interaction between medicinal mushroom polysaccharides and standard human papillomavirus management.
- HSIL/CIN 2-3 carries a real progression risk — the progression risk to invasive cancer is real, and definitive excisional treatment is the standard management when indicated; a supplement trial does not remove that risk.
- Human papillomavirus vaccination remains the gold standard primary prevention for unexposed individuals. Turkey Tail does not substitute for human papillomavirus vaccination, and in women with human papillomavirus exposure vaccination can still prevent infection with types they have not yet been exposed to.
- The window the supplement studies targeted — persistent infection with normal-to-low-grade cytology, where conventional medicine offers watchful waiting and the immune-mediated clearance mechanism is what the supplements are meant to support.
In 2026 FIGO (the International Federation of Gynecology and Obstetrics) and the International Gynecologic Cancer Society (IGCS) issued a position statement on topical treatments for high-risk human papillomavirus and LSIL, including Coriolus versicolor-based vaginal gels. They found that “No randomized controlled trial has been adequately designed or powered” to evaluate the effect of topical therapies on the prevention of histologically confirmed HSIL/CIN3+. For the Coriolus versicolor-based and silicon dioxide/selenite-based gels, they reported “retrospective trial registration, industry funding, and misinterpretation of findings consistent with the spin phenomenon.” The statement says FIGO and IGCS “do not endorse the routine clinical use of any currently available topical agent for HR-HPV infection or LSIL” and that evidence-based surveillance remains the standard of care.
For more on human papillomavirus management broadly, see our human papillomavirus page.
Other Human Papillomavirus-Associated Sites (Oropharyngeal, Anal)
Human papillomavirus does not infect only the cervix. The same high-risk types cause cancers of the oropharynx (rising rapidly in incidence in developed countries, now exceeding cervical cancer in some Western populations), anus, vulva, vagina, and penis. The Donatini 2014 preliminary randomized study specifically addressed oral human papillomavirus with combined Coriolus / Ganoderma therapy for 2 months in people with gingivitis, reporting 88% clearance of HPV-16/18 on mouth swabs, against 5% in the comparison group.
The immune mechanism of clearance is the same at all anatomic sites: natural killer cell-mediated elimination of infected keratinocytes followed by dendritic cell-coordinated adaptive responses. Patients with oropharyngeal human papillomavirus (often detected on incidental dental or ear, nose and throat (ENT) examination) or anal human papillomavirus (detected on screening anal Pap in high-risk populations) fall outside what the cervical trials studied, and the formal clinical trial evidence for these sites is thinner.
Cautions and Limitations of the Evidence
- The AHCC vs Turkey Tail distinction — the highest-quality clinical evidence (Smith 2022 randomized trial) is for AHCC specifically, not Turkey Tail. AHCC is a related but distinct shiitake-mycelium-derived extract. Mechanistic overlap is substantial but not complete.
- Sample sizes are small — even the Smith 2022 trial enrolled only 50 women, of whom 41 completed it. Larger Phase III confirmation is needed.
- Clearance is not eradication — a "cleared" human papillomavirus polymerase chain reaction test means the virus is below the detection limit of the assay; latent virus may still be present in basal cells. Recurrence is possible.
- Not effective for HSIL/CIN 2-3 — these lesions require definitive excisional treatment; supplements have not been shown to replace indicated LEEP or conization.
- Pregnancy — there is insufficient safety data on use during pregnancy
- Immunosuppressive medication — the mechanism of human papillomavirus clearance is host immune-mediated. Patients on immunosuppressive therapy (post-transplant, biologic disease, ongoing chemotherapy) are unlikely to benefit because the rate-limiting step (host immunity) is pharmacologically suppressed.
- Side effects — mild gastrointestinal (GI) upset in 10-15% of users; rare allergic reactions
- Overall quality of the evidence — a 2024 scoping review of complementary and alternative treatments for human papillomavirus and cervical dysplasia identified 2324 studies, of which 56 met its criteria. It found the most clinical benefit and best randomized support for topical mushroom (Coriolus versicolor) gel, oral and topical selenium, and oral indole-3-carbinol, but rated the evidence “of low quality,” and only 28 of 56 studies (50%) reported adverse events.
Key Research Papers
- Smith JA, Gaikwad AA, Mathew L, Rech B, Faro JP, Lucci JA 3rd, Bai Y, Olsen RJ, Byrd TT (2022). AHCC® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections. Frontiers in Oncology 12:881902. — PubMed PMID: 35814366
- Smith JA, Mathew L, Gaikwad A, Rech B, Burney MN, Faro JP, Lucci JA 3rd, Bai Y, Olsen RJ, Byrd TT (2019). From Bench to Bedside: Evaluation of AHCC Supplementation to Modulate the Host Immunity to Clear High-Risk Human Papillomavirus Infections. Frontiers in Oncology 9:173. — PubMed PMID: 30949451
- Donatini B (2014). Control of oral human papillomavirus (HPV) by medicinal mushrooms, Trametes versicolor and Ganoderma lucidum: a preliminary clinical trial. International Journal of Medicinal Mushrooms. — PubMed PMID: 25271984
- Serrano L, López AC, González SP, Palacios S, Dexeus D, Centeno-Mediavilla C, Coronado P, de la Fuente J, López JA, Vanrell C, Cortés J (2021). Efficacy of a Coriolus versicolor-Based Vaginal Gel in Women With Human Papillomavirus-Dependent Cervical Lesions: The PALOMA Study. Journal of Lower Genital Tract Disease. — PubMed PMID: 33746195
- Højen IB, Kristensen MK, Bertelsen VM, Tranberg M, Petersen LK, Andersen B, Bor P (2026). Effect of coriolus versicolor-based vaginal gel on clearance of human papillomavirus and cervical dysplasia - a scoping review. BMC Women’s Health. — PubMed PMID: 41507892
- Pareja R, Heredia F, Sánchez-Díaz E, et al. (2026). FIGO/IGCS Statement on the efficacy of topical treatments for high-risk human papillomavirus in preventing CIN 3+ lesions. International Journal of Gynecological Cancer. — PubMed PMID: 42680632
- Walsh CJ, Friedman JC, Piper C, Conageski C (2024). A Scoping Review of Complementary and Alternative Medicine for Human Papillomavirus Infections and Cervical Dysplasia. Journal of Lower Genital Tract Disease. — PubMed PMID: 38697129
- Stanley M (2010). HPV - immune response to infection and vaccination. Infectious Agents and Cancer. — PubMed PMID: 20961432
- Schiffman M et al. (2016). Carcinogenic human papillomavirus infection. Nature Reviews Disease Primers. — PubMed PMID: 27905473
- Sasagawa T, Takagi H, Makinoda S (2012). Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. Journal of Infection and Chemotherapy. — PubMed PMID: 23117294
- Cuschieri KS, Cubie HA, Whitley MW, Gilkison G, Arends MJ, Graham C, McGoogan E (2005). Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. Journal of Clinical Pathology. — PubMed PMID: 16126875